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ABSTRACT 
 
Diagnostic distinction of primary progressive aphasias (PPA) remains challenging, in 
particular for the logopenic (lvPPA) and nonfluent/agrammatic (naPPA) variants. Recent 
findings highlight that episodic memory deficits appear to discriminate these PPA variants 
from each other, as only lvPPA perform poor on these tasks while having underlying amyloid 
pathology similar to that seen in amnestic dementias like Alzheimer’s disease (AD). Most 
memory tests are, however, language based and thus potentially confounded by the prevalent 
language deficits in PPA. The current study investigated this issue across PPA variants by 
contrasting verbal and non-verbal episodic memory measures while controlling for their 
performance on a language subtest of a general cognitive screen. A total of 203 participants 
were included (25 lvPPA; 29 naPPA; 59 AD; 90 controls) and underwent extensive verbal 
and non-verbal episodic memory testing, with a subset of patients (n=45) with confirmed 
amyloid profiles as assessed by Pittsburgh Compound B (PiB) and PET. The most powerful 
discriminator between naPPA and lvPPA patients was a non-verbal recall measure (Rey 
Complex Figure delayed recall), with 81% of PPA patients classified correctly at presentation. 
Importantly, AD and lvPPA patients performed comparably on this measure, further 
highlighting the importance of underlying amyloid pathology in episodic memory profiles. 
The findings demonstrate that non-verbal recall emerges as the best discriminator of lvPPA 
and naPPA when controlling for language deficits in high load amyloid PPA cases. 
 
 
Keywords: Memory, Primary Progressive Aphasia, Logopenic Progressive Aphasia, 
Progressive Nonfluent Aphasia, PiB 
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INTRODUCTION 
Primary Progressive Aphasia (PPA) is a neurodegenerative clinical syndrome characterized 
by an isolated language disorder at presentation. International Consensus Diagnostic Criteria 
for PPA have been proposed [1] with three clinical variants of the condition being recognized 
- a semantic variant (svPPA), and two non-semantic variants termed nonfluent/agrammatic 
(naPPA) and logopenic (lvPPA) variants of PPA. Briefly, svPPA presents with loss of object 
and word meaning amongst grammatically correct and fluent speech. In contrast, naPPA 
presents with relatively preserved word comprehension but with apraxia of speech and/or 
grammatical errors in speech making these patients’ speech labored and ‘nonfluent’. lvPPA 
presents with anomia and marked difficulties in sentence repetition, amidst variable 
phonological errors in speech, preserved grammar (unlike naPPA), and single word 
comprehension (unlike svPPA) [1, 2].  
 
Nevertheless, the distinction between the different PPA subtypes remains clinically 
challenging, in particular for lvPPA and naPPA. By contrast, clinical diagnosis of svPPA has 
been established for a long time [3] and its initial symptoms and pattern of progression stand 
out from the other two variants of PPA. The separation of lvPPA, and naPPA is complex due 
to overlap in symptoms, in that the former make phonological errors and the latter also have 
errors in speech production on the basis of impaired articulatory planning [4]. In the absence 
of explicit guidelines on measuring these linguistic features, it becomes clear that there is a 
need to establish other cognitive biomarkers that can reliably distinguish both presentations. 
 
Such cognitive biomarkers might be in particular relevant to detect the underlying pathology 
of both presentations. This is particularly relevant for lvPPA, as amyloid imaging studies with 
positron emission tomography (PET) have shown that lvPPA patients present with a similar 
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prevalence of high amyloid as patients with Alzheimer’s disease (AD) [5]. By contrast naPPA 
patients present with predominately low amyloid burden likely due to the prevalent 
underlying tauopathy. The difference in this underlying pathology between naPPA and lvPPA 
raises the question as to whether lvPPA show deficits in episodic memory and orientation 
similar to AD, in addition to the prevalent language deficits. If so, can performance on 
particular tests of memory be employed as proxy measures in discriminating an underlying 
amyloid (lvPPA) from a non-amyloid (naPPA) PPA syndrome? Two previous studies by our 
group investigated this issue [6, 7] and indeed showed that only lvPPA patients are impaired 
on episodic memory testing, whereas naPPA patients perform at a similar level as age-
matched controls. Neither study specifically investigated whether the episodic performance in 
lvPPA might have been affected by the modality (verbal vs. non-verbal) of the episodic 
memory tests employed. In particular, one should assume that verbal episodic test 
performance might be confounded by the language deficits in lvPPA, whereas non-verbal 
episodic memory might give a more accurate memory profile in lvPPA. Such findings would 
have immediate clinical implications, as these tests could possibly substitute more expensive 
and invasive methods such as amyloid imaging and lumbar puncture to confirm underlying 
pathology. 
 
The current study set out to address this issue by contrasting verbal and non-verbal episodic 
memory measures in lvPPA and naPPA, while controlling for language deficits. Episodic 
memory performance was also compared to AD and age-matched controls. Importantly, a 
subset of patients had undergone amyloid imaging with PET to corroborate our findings. We 
hypothesized that lvPPA would be impaired on episodic memory tests compared to naPPA, 
confirming previous results. We further hypothesized that lvPPA would perform on an 
episodic performance level similar to AD and that non-verbal memory measures would allow 
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the highest discrimination between lvPPA and naPPA, when controlling for overall language 
deficits. 
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MATERIALS AND METHODS 
 
Patients meeting the consensus criteria were recruited from the Frontotemporal Dementia 
Clinic at Neuroscience Research Australia in Sydney. Diagnosis of PPA (25 lvPPA, 29 
naPPA) was based on the International Consensus Criteria [1] using the clinical methods 
described in detail elsewhere [5]. A diagnosis of AD was made based on the diagnostic 
consensus criteria [8]. Forty-five patients (17 lvPPA, 13 naPPA, 15 AD) underwent a an 
amyloid imaging PET study with 11C-Pittsburgh compound B (PiB) at the Austin Health 
Centre for PET in Melbourne, Australia.  PiB retention was determined as the standardized 
uptake value ratio (SUVR) using the cerebellar cortex as reference region [5]. Neocortical 
SUVR was defined as the average SUVR of frontal, superior parietal, lateral temporal, lateral 
occipital and cingulate regions. A cut-off ratio of 1.5 was use to dichotomize between ‘high’ 
and ‘low’ neocortical SUVR. All AD and lvPPA cases showed high neocortical SUVR (‘PiB 
positive’), while all naPPA cases showed low neocortical SUVR (‘PiB negative’). Data from 
the PiB-PET subset of patients were used in a confirmatory manner, adding to the results 
obtained from the whole-group analysis. Healthy control subjects (n=90) were selected from 
the Frontier volunteer panel and age- and education-matched to the patient groups. This panel 
comprises of healthy elderly participants recruited from the community and screened via a 
general cognitive test (the Addenbrooke’s Cognitive Examination – Revised (ACE-R) that 
includes memory, language, visuospatial, and orientation sub domain scores [9]. At testing, 
these healthy participants are also tested on a detailed neuropsychological battery, and 
undergo standard questionnaires to screen for neuropsychiatric symptoms and structural 
neuroimaging. All healthy controls performed within normal range on these measures. All 
patients were tested on a general cognitive screen – the ACE-R. Particularly, the ACE-R 
language domain score that was used a covariate for statistical analysis, comprises of short 
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language tasks of single word and sentence comprehension, writing, single word and sentence 
repetition, and reading. 
Carers of patients completed a neuropsychiatric screening questionnaire (Cambridge 
Behavioral Inventory revised, CBI-R [10]). This questionnaire comprises of questions 
regarding abnormalities in the patient’s behaviour, memory, mood, eating and sleeping habits, 
and was used to determine memory problems in the patient as gauged by the carer. Disease 
severity was assessed using the Rasch score of the Frontotemporal Dementia Rating Scale 
(FRS) [11]. This scale ranks dementia severity based on different behavioral changes and 
impairments in everyday functioning that characterize frontotemporal dementia, of which 
PPA syndromes can be variants, with lower Rasch scores indicating greater disease severity. 
The South Eastern Sydney and Illawarra Atrea Health Service and the University of New 
South Wales human ethics committees approved the study and written informed consent was 
obtained from the participant or the primary caregiver in accordance with the Declaration of 
Helsinki.  
 
Neuropsychological tests 
Verbal recall and recognition were assessed using the Rey Auditory Verbal Learning Test 
(RAVLT) [12] and components from the memory domain (address learning, delayed address 
recall, retrograde memory, and address recognition) from the ACE-R. In the RAVLT, 
participants are presented with a list of 15 unrelated words that are repeated over five trials. 
Participants are required to recall as many words as they remember at the end of each trial as 
well as over a filled (with non-verbal tasks) delay of 30 minutes. No non-verbal memory tasks 
were administered during the delay. Following the delayed recall, a recognition component is 
administered where participants are required to correctly indicate intra-list words amongst 
foils. The RAVLT scoring yields total number of words recalled in each trial, number of 
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words correctly recognized in the recognition component, as well as indices of learning over 
the five trials (Short Term Percentage Retention (STPR) calculated as immediate recall (A6) 
/final trial learning (A5)*100) and delay (Long Term Percentage Retention (LTPR) calculated 
as delayed recall (A7)/final trial learning (A5)*100) expressed as percentages. Only the 
RAVLT STPR, LTPR, and recognition components were considered here. Non-verbal recall 
was assessed using a three-minute delayed recall of the Rey-Osterrieth Complex Figure 
(ROCF) [13]. Here, participants are shown a complex figure and asked to copy it. The figure 
and its copy are then hidden and participants are required to draw as much of the figure as 
they can recall, testing incidental learning. After 3 minutes, a delayed recall is also 
administered and scoring comprises of number of correct components of the complex figure 
that participants were able to recall [14]. Non-verbal recognition was assessed using the 
Doors component (set A) from the Doors and People Test [15]. Here, participants are shown 
colored photographs of 12 ‘target’ doors. Each is followed by a presentation of four doors 
(one target and three foils of the same general label (e.g. barn door)) where the subject picks 
out the target door. A maximum score of 12 can be attained and if subjects score more than 9 
on set A, they proceed to a more difficult set B. Only a small percentage of our patient group 
managed to proceed to set B, therefore, scores from only set A are considered here. A trained 
neuropsychologist (E.F.) administered and scored all neuropsychological performances. 
 
Composite scores for verbal memory recall (comprising of scores from address learning, 
delayed address recall, and retrograde memory measures of the ACE-R and the STPR and 
LTPR measures of the RAVLT), verbal memory recognition (comprising of ACE-R address 
recognition and RAVLT list recognition), non-verbal memory recall (comprising of the 
ROCF three-minute delayed recall score) and non-verbal memory recognition (comprising of 
the Doors Test A raw score) were calculated by converting individual raw test scores into 
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percentages (dividing the test score by maximum possible score and multiplying the result by 
100), grouping the tests into their respective verbal and non-verbal recall and recognition 
domains and deriving averages of all percentage test values within each domain. 
 
Statistics 
Results were calculated using RStudio v2.13.1. Prior to any analysis, variables were plotted 
and checked for normality of distribution via Shapiro-Wilk tests. An analysis of variance 
(ANOVA) was used to compute mean differences for demographic data across groups. We 
performed an analysis of covariance (ANCOVA) to investigate how overall language deficits 
and disease severity impacted episodic memory performance. The ANCOVA thus computed 
group differences in patients for episodic memory data while controlling for disease severity 
(FRS Rasch score) and overall language impairment (ACE-R language score). The ACE-R 
language score was used as a covariate as its composite score comprising of single word and 
sentence comprehension, writing, single word and sentence repetition, and reading tests 
provides an overall impression of language performance in these patients. While post-hoc 
differences for demographic data were calculated using ‘false discovery rate’ method, post-
hoc differences between groups for neuropsychological data were calculated using the 
‘Tukey’s HSD’ method. These statistical procedures were further repeated on patients divided 
into high and low neocortical SUVR groups. Logistic regressions were then performed in 
order to evaluate diagnostic accuracy for both composite and specific neuropsychological 
measures between PPA groups.  
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RESULTS 
 
Demographics 
Demographics, MMSE, ACE-R, and CBI-R scores for all participants are presented in Table 
1. All groups were matched for age, gender, and education and all patient groups were 
matched for disease duration (all p values >.1). There was a significant group effect of disease 
severity as measured by the FRS [F(2,81) = 7.62; p<0.001]. Severity of disease was 
significantly greater in AD patients as compared to both naPPA (p<0.001) and lvPPA 
(p<0.05) groups. Importantly, the lvPPA and naPPA groups did not differ significantly on 
disease severity (p>.1). Within patient groups, no significant differences were noted on 
demographic or disease-related variables between participants who did not undergo and those 
who underwent PiB-PET scans (p>.1). 
 
<INSERT TABLE 1 HERE> 
 
Cognitive screening  
When corrected for disease severity, significant group effects emerged for ACE-R language 
[F(2,80) = 10.08; p<0.001], ACE-R memory [F(2,80) = 4.30; p<0.05] subdomains, and 
overall ACE-R performance [F(2,80) = 7.57; p<0.001] between patient groups. The lvPPA 
group performed poorer than both AD and naPPA groups on the ACE-R memory and ACE-R 
total scores (both p values <0.05), and poorer than the AD group on the ACE-R language 
domain (p<0.001). On the CBI-R memory component, significant group differences emerged 
[F(3,174) = 57.02; p<0.001], wherein carers of patients with AD endorsed the most number 
of memory problems, which was significantly higher than both PPA groups (p<0.01). Carers 
of patients with lvPPA endorsed significantly more number of memory complaints (p<0.001) 
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compared to carers of naPPA patients and all patient groups had higher endorsement of 
memory problems than controls (p<0.01). 
 
Episodic memory – composite scores 
Composite scores for verbal and non-verbal recall and recognition corrected for disease 
severity and language impairment are presented in Figure 1 and Table 2. Significant group 
effects emerged only for composite verbal recall [F(2,79) = 3.71; p<0.05] and non-verbal 
recall [F(2,71) = 20.57; p<0.001] performance. The naPPA group performed significantly 
better than the AD group on verbal memory recall (p<0.05) and significantly better than both 
lvPPA and AD groups on non-verbal memory recall (p<0.001). No significant differences 
were found between AD and lvPPA groups on any of the measures.  
<INSERT FIGURE 1 HERE> 
 
<INSERT TABLE 2 HERE> 
 
Episodic memory – test specific scores  
The composite findings were followed up by an ANCOVA (correcting for disease severity 
and language impairment) on all neuropsychological test measures to test overall and 
between-group differences (Table 3). Uncorrected and individually corrected (for disease 
severity and for language impairment) p-values for the whole group’s performance are 
depicted in Table 4. 
 
<INSERT TABLE 3 HERE> 
 
<INSERT TABLE 4 HERE> 
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On tests of verbal recall and recognition, all patient groups performed comparably except on 
the address recall task from the ACE-R [F(2,79) = 8.15; p<0.001], on which the lvPPA group 
scored lower than the naPPA group (p<0.001). Group differences also emerged on tests of 
non-verbal ROCF copy [F(2,72) = 3.59; p<0.05] and recall [F(2,71) = 20.57; p<0.001]. On 
the ROCF copy, the AD group performed poorer than the naPPA group (p<0.05), while on 
the ROCF recall measure, the lvPPA and AD groups performed comparably, but poorer than 
the naPPA group (both p values <0.001). Post-hoc tests on the non-verbal recognition 
measure (Doors test) revealed no significant differences between patient groups.  No other 
significant differences between patient groups were found. 
 
Amyloid – episodic memory relationship 
Episodic memory performance for the amyloid subgroup’s performance (PiB positive vs. 
negative) are depicted in Table 4. Analysis involving patients with PiB scans revealed an 
identical pattern as the whole group analysis. When corrected for both disease severity and 
language impairment, group differences emerged on ACE-R retrograde memory [F(2,31) = 
5.57; p<0.01] and ROCF delayed recall measure [F(2,31) = 7.03; p<0.01]. The lvPPA group 
performed poorer than the naPPA group only on the ACE retrograde memory and ROCF 
delayed recall measures (both p values <0.05), and the lvPPA and AD group performed 
comparably on all measures (p<0.1). Within each patient group, no significant differences 
emerged on episodic memory data between participants who underwent PiB-PET and those 
who did not undergo amyloid imaging (all p values >.1) 
 
Logistic Regression and cut-off scores 
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Area under the curve was computed on lvPPA and naPPA patient groups to determine how 
well composite and specific verbal and non-verbal memory tests could discriminate both 
groups.  
The non-verbal recall composite score emerged as the strongest discriminator between lvPPA 
and naPPA patients (distinguishing 81.3% of the sample) followed by verbal recall 
(distinguishing 73.9% of the sample) and verbal recognition (distinguishing 65.7% of the 
sample) composite scores. The weakest discriminatory measure was the non-verbal 
recognition composite score (distinguishing 47.9% of the sample).  
Amongst individual tests, the two strongest discriminatory measures that emerged were the 
ROCF delayed recall and the ACE-R address delayed recall, successfully discriminating 
81.3% and 75.3% of the sample at clinic presentation respectively. For lvPPA and naPPA 
patients with PiB-PET scans, this distinction increased to 84.2% and 83.3% of the sample 
respectively successfully classified at clinic presentation solely based on the ROCF delayed 
recall and ACE-R address delayed recall measures. Additionally, while the ACE retrograde 
memory measure discriminated 71.2% of lvPPA and naPPA patients in the overall group, this 
measure successfully discriminated 90.5% of lvPPA and naPPA patients in the high 
neocortical SUVR group, making this the strongest discriminator between lvPPA and naPPA 
patients with PiB-PET scans.  
We established cut-off scores on the ROCF delayed recall and ACE-R address recall 
measures to determine their diagnostic specificity for lvPPA and naPPA. A cut-off score of 15 
(max = 36) on the ROCF delayed recall and a cut-off of 3 (max = 7) on the ACE-R address 
delayed recall distinguished both groups significantly in a chi-square test (p<0.05), with 90% 
of lvPPA patients and 33% of naPPA patients respectively, performing below both cut-offs. 
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DISCUSSION 
 
Our results indicate that episodic memory measures are reliable cognitive biomarkers to 
distinguish lvPPA and naPPAs. After controlling for both disease severity and language 
impairment, only a delayed recall and non-verbal recall measure appeared to be particularly 
strong in discriminating both PPA groups. More importantly, non-verbal episodic memory 
measures, such as the ROCF were the most sensitive memory measures to dissociate amyloid 
based PPAs (i.e. lvPPA) from those with underlying tauopathies (i.e. naPPA). Thus modality 
of episodic memory task emerges as an important factor to have the most sensitive and 
specific discrimination of PPAs, when controlling for overall language deficits. 
 
In more detail, we replicated previous findings showing that episodic memory is significantly 
impaired in lvPPA compared to naPPA and can act as a potential diagnostic biomarker for the 
underlying amyloid pathology in lvPPA [6,7]. More importantly, the study findings suggest 
that non-verbal recall provides the clearest distinction of naPPA and lvPPA patients when 
controlling for language deficits. Particularly, the ROCF delayed recall measure emerged as 
the most sensitive discriminator between lvPPA and naPPA, possibly because this measure 
may not have been directly impacted by language deterioration in the course of the disease. 
While one may argue that this could reflect a visuospatial deficit in copying and drawing in 
lvPPA [16], our results clearly indicate that the lvPPA group performed comparably to both 
naPPA and AD groups on the ROCF copy suggesting operation of a larger deficit in non-
verbal recall rather than in visuospatial abilities in lvPPA. While our non-verbal recall 
measure emerged sensitive, the non-verbal recognition test (Doors Test) was not a powerful 
discriminator between PPA syndromes, echoing similar results found using this test in 
patients with AD and frontotemporal dementia [17].   
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Previously, diagnostic distinction of PPA subtypes has mainly relied on various assessments 
of language and connected speech to distinguish naPPA from lvPPA [18-21]. Based on these, 
some have accurately classified as high as 88% of these patients using measures of acoustic 
speech production [20], up to 87% on a short language battery [21] and additionally up to 
81% based on automated structural magnetic resonance imaging algorithms [22]. Classifying 
lvPPA patients on the basis of language tests has also been acknowledged to produce a false 
positive rate as high as 14% [21] casting doubt on whether one should rely solely on heavily 
language-oriented tasks to aid discrimination between these conditions. There is also the 
problem that PPA patients show overlapping features with lvPPA producing phonological 
errors and naPPA articulatory or phonetic deficits on the basis of apraxia of speech [4]. Non-
verbal memory tasks, on the other hand, have been less explicitly tested for their diagnostic 
utility with few studies reporting deficits on these tests [7, 23] although the current findings 
replicate prior results.  
 
The finding that groups with underlying Alzheimer pathology (AD and lvPPA) performed 
comparably on the ROCF delayed recall measure and poorer than the naPPA group, suggests 
that a non-verbal episodic memory task may aid in discriminating an underlying Alzheimer 
from a non-Alzheimer pathology based PPA syndrome. This finding is strengthened by 
identical results from patients with confirmatory PiB-PET scans, where the ROCF delayed 
recall measure discriminated close to 85% of PPA patients. Further support for this comes 
from early evidence for amyloid pathology to have strong links with scores on memory and 
orientation domains of the ACE-R, deficits on which are especially notable in amyloid related 
PPA syndromes [6]. One surprising finding was that the delayed address recall of the ACE 
test also discriminated both groups very well, even when corrected for language deficits. 
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Similarly, the ACE retrograde memory measure discriminated both PiB-confirmed PPA 
groups up to 90%. Thus, retrieval delay and semantic memory might be other important 
factors, in addition to non-verbal test material, for episodic memory testing in PPAs. 
 
The current findings have both clinical and theoretical implications. When testing PPA 
patients, in addition to the suggested cut-off of 22 on the ACE-R memory domain (in [6]), if 
patients score less than 15 on the ROCF delayed recall and less than 3 on the ACE-R address 
delayed recall, it is likely that the patient has lvPPA, which can then be further confirmed 
using amyloid imaging. The suggested ROCF cut-off may also be particularly helpful for 
clinicians when assessing PPA patients who do not speak the same languages as them. 
Theoretically, amyloid deposition in the brain has been noted to be critical and strongly 
related to episodic memory performance, even in healthy adults [24]. Considering that both 
AD and lvPPA are characterized by high amyloid in the brain, lvPPA is likely to represent a 
language-onset variant of AD instead of a clinical variant of PPA [25]. This speculation needs 
further confirmatory evidence.  
 
In summary, the findings suggest that a non-verbal episodic memory measure and a delayed 
recall measure would be useful as proxy measures for discriminating between non-semantic 
PPA syndromes as well as between Alzheimer and non-Alzheimer pathologies when used as 
part of a comprehensive neuropsychological test battery. Despite these promising findings, 
there were some limitations in this study, such as that only a subset of patients had 
pathological amyloid imaging confirmation, although the PiB group did not differ from the 
remaining patients for the observed deficits. This may have reduced the power for the PiB 
subgroup’s analysis. Similarly, as a larger number of exploratory analyses were performed 
here, this could also have potentially increased chances of type-1 errors. Another limitation of 
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the current study was that we used percentages instead of raw or standardized scores in our 
composite score calculation. We also did not include PPA patients with mixed or atypical 
features and svPPA patients. We also used the FRS as a measure of disease severity and 
though this scale has been validated in PPA patients [11], this measure may not have 
accurately captured disease severity in AD. Future studies should address these issues as well 
as attempt to understand if episodic memory deficits present early in the course of the disease 
could aid in differentially classifying lvPPA from AD. These would clearly have implications 
to more accurate diagnosis of lvPPA as the current PPA diagnostic criteria exclude 
pronounced memory impairment in early stages of the disease. Finally, future studies should 
investigate: i) the relationship between AD, lvPPA and combinations of underlying tau and 
amyloid pathophysiology and ii) how neuroanatomical substrates of non-verbal memory 
deficits in these patients correlate with current imaging evidence demonstrating predominant 
left-sided temporoparietal atrophy in lvPPA. 
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Table 1. Demographics and cognitive screen scores for all groupsa 
 
Note. aStandard deviations shown in brackets, maximum score for tests shown in brackets. 
lvPPA, Logopenic variant – Primary Progressive Aphasia; naPPA, Nonfluent/agrammatic 
variant – Primary Progressive Aphasia; AD, Alzheimer’s disease; FRS, Frontotemporal 
Dementia Rating Scale; MMSE, Mini Mental Status Examination, ACE-R, Addenbrooke’s 
Cognitive Examination – Revised; CBI-R – Cambridge Behavioral Inventory – Revised. 
 *, p<0.05; **, p<0.01; ***, p<0.001; n.s., not significant 
 lvPPA naPPA AD Controls Group 
effect 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
naPPA 
vs. 
AD 
n 25 29 59 90     
Gender 
(m: f) 
10:15 14:15 37:22 38:52 n.s. n.s. n.s. n.s. 
Age 68.72 
(7.63) 
72.06 
(10.04) 
68.33 
(8.40) 
70.35 
(7.10) 
n.s. n.s. n.s. n.s. 
Education 
(years) 
12.83 
(3.42) 
12.00 
(3.05) 
12.50 
(3.70) 
13.07 
(3.06) 
n.s. n.s. n.s. n.s. 
Disease 
duration 
(months) 
47.76 
(32.47) 
38.17 
(26.25) 
38.88 
(22.58) 
- n.s. n.s. n.s. n.s. 
FRS 
(Rasch) 
1.65 
(1.77) 
2.12 
(1.59) 
0.64 
(1.25) 
- *** n.s. * *** 
MMSE 
total (30) 
19.60 
(4.53) 
24.00 
(5.12) 
21.45 
(5.70) 
29.24 
(0.81) 
* n.s. n.s. n.s. 
ACE-R 
total (100) 
53.08 
(14.05) 
69.72 
(17.92) 
64.84 
(19.13) 
91.31 
(3.22) 
*** * *** n.s. 
ACE-R 
memory 
(26) 
12.36 
(5.49) 
18.44 
(8.05) 
13.77 
(6.11) 
24.18 
(1.83) 
* * * n.s. 
ACE-R 
language 
(26) 
16.08 
(4.76) 
18.93 
(4.56) 
21.03 
(4.95) 
25.12 
(1.06) 
*** n.s. *** * 
CBI-R 
Memory 
(%) 
37.44 
(18.74) 
21.13 
(20.39) 
49.40 
(23.29) 
8.21 
(9.25) 
*** *** ** *** 
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Table 2. Mean percentages of performance for all groups on composite recall and recognition  
measuresa 
Note. aStandard deviations in brackets; Verbal memory recall composite score comprised of 
scores from the address learning, delayed address recall, and retrograde memory measures of 
the ACE-R and the STPR and LTPR measures of the RAVLT; Verbal memory recognition 
composite score comprised of ACE-R address recognition and RAVLT list recognition; Non-
verbal memory recall composite score comprised of the ROCF three-minute delayed recall; 
Non-verbal memory recognition composite score comprised of the Doors Test A raw scores; 
lvPPA, Logopenic variant – Primary Progressive Aphasia; naPPA, Nonfluent/agrammatic 
variant – Primary Progressive Aphasia; AD, Alzheimer’s disease. 
 *, p<0.05; **, p<0.01; ***, p<0.001; n.s., not significant 
Neuropsychological 
measures 
lvPPA naPPA AD Controls Group 
effect 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. 
AD 
naPPA 
vs. 
AD 
Verbal memory recall 41.69% 
(24.08%) 
66.15% 
(32.43) 
45.63% 
(23.60%) 
88.98% 
(0.90%) 
* n.s. n.s. * 
Verbal memory 
recognition 
72.40% 
(26.44%) 
82.64% 
(25.57%) 
71.63% 
(22.52%) 
93.03% 
(0.87%) 
n.s. n.s. n.s. n.s. 
Non-verbal memory 
recall 
18.18% 
(14.56) 
39.52% 
(20.11%) 
12.79% 
(14.20%) 
47.40% 
(16.89%) 
*** *** n.s. *** 
Non-verbal memory 
recognition 
79.16% 
(0.19%) 
79.33% 
(0.14%) 
63.60% 
(0.18%) 
91.44% 
(9.14%) 
* n.s. n.s. n.s. 
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Table 3. Performance of all groups on neuropsychological measures (controlled for disease severity and language impairment)a 
Note. aStandard deviations shown in brackets, maximum score for tests shown in brackets. lvPPA, Logopenic variant – Primary Progressive 
Aphasia; naPPA, Nonfluent/agrammatic variant – Primary Progressive Aphasia; AD, Alzheimer’s disease; ACE-R, Addenbrooke’s Cognitive 
Examination – Revised; RAVLT, Rey Auditory Verbal Learning Test; STPR, Short-term percentage retention; LTPR, Long-term percentage 
retention; ROCF, Rey-Osterrieth Complex Figure. *, p<0.05; **, p<0.01; ***, p<0.001; n.s., not significant 
Measures lvPPA naPPA AD Controls Group 
effect 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
naPPA 
vs. AD 
n 25 29 59 90     
Verbal Memory – Recall       
ACE-R address learning (7) 3.96 (2.09) 5.58 (2.48) 5.20 (2.23) 6.97 (0.14) n.s. n.s. n.s. n.s. 
ACE-R address delayed recall (7) 1.56 (1.95) 4.13 (2.70) 1.57 (2.07) 5.97 (1.15) *** *** n.s. *** 
ACE-R retrograde memory (4) 1.72 (1.13) 2.68 (1.51) 2.13 (1.41) 3.68 (0.57) n.s. n.s. n.s. n.s. 
RAVLT STPR (%) 55.00 (38.36) 71.20 (28.28) 49.43 (34.03) 82.45 (17.05) n.s. n.s. n.s. n.s. 
RAVLT LTPR (%) 62.33 (41.61) 70.86 (38.49) 33.28 (36.75) 81.76 (19.01) n.s. n.s. n.s. n.s. 
Verbal Memory – Recognition       
ACE-R address recognition (7) 3.68 (1.40) 4.13 (1.38) 3.72 (1.27) 4.76 (0.49) n.s. n.s. n.s. n.s. 
RAVLT recognition (15) 12.66 (1.32) 13.53 (2.77) 10.58 (3.02) 13.49 (1.54) n.s. n.s. n.s. n.s. 
Non-verbal Memory – Recall       
ROCF copy (36) 24.86 (8.19) 30.11 (4.15) 23.28 (11.06) 32.10 (2.99) * n.s. n.s. * 
ROCF 3-minute delayed recall (36) 6.54 (5.24) 14.23 (7.24) 4.60 (5.11) 17.06 (6.08) *** *** n.s. *** 
Non-verbal Memory – Recognition       
Doors Test A (Raw score) (12) 9.50 (2.32) 9.52 (1.78) 7.63 (2.20)  10.97 (1.09) n.s. n.s. n.s. n.s. 
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Table 4. Uncorrected and individually corrected p-values for pairwise comparisons on episodic memory test measures 
 Whole group analysis PiB subgroup analysis 
Uncorrected Corrected for 
disease severity 
Corrected for 
language deficit 
Uncorrected Corrected for 
disease severity 
Corrected for 
language deficit 
lvPPA 
vs. AD 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
lvPPA 
vs. 
naPPA 
lvPPA 
vs. AD 
lvPPA 
vs. 
naPPA 
Verbal Memory – Recall   
ACE-R address 
learning 
* ** *** n.s. n.s. n.s. n.s. ** ** ** n.s. n.s. 
ACE-R address 
delayed recall 
n.s. *** n.s. ** * *** n.s. *** n.s. ** n.s. n.s. 
ACE-R 
retrograde 
memory 
n.s. ** n.s. n.s. n.s. n.s. n.s. ** n.s. *** n.s. n.s. 
RAVLT STPR n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
RAVLT LTPR * n.s. n.s. n.s. ** n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Verbal Memory – 
Recognition  
 
ACE-R address 
recognition 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
RAVLT 
Recognition 
n.s. n.s. n.s. n.s. ** n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Non-verbal Memory – 
Recall  
 
ROCF copy n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
ROCF 3-
minute delayed 
recall 
n.s. *** n.s. *** n.s. *** n.s. ** n.s. ** n.s. * 
Non-verbal Memory – 
Recognition  
 
Doors Test A 
(Raw score) 
*** n.s. n.s. n.s. *** n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
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Note. lvPPA, Logopenic variant – Primary Progressive Aphasia; naPPA, Nonfluent/agrammatic variant – Primary Progressive Aphasia; AD, 
Alzheimer’s disease. ACE-R, Addenbrooke’s Cognitive Examination – Revised; RAVLT, Rey Auditory Verbal Learning Test; STPR, Short 
Term Percentage Retention; LTPR, Long Term Percentage Retention; ROCF, Rey-Osterrieth Complex Figure. 
 *, p<0.05; **, p<0.01; ***, p<0.001; n.s., not significant 
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Figure 1. Composite scores for verbal and non-verbal recall and recognition measures for all 
groups 
 
 
 
Note. lvPPA, Logopenic variant – Primary Progressive Aphasia; naPPA, 
Nonfluent/agrammatic variant – Primary Progressive Aphasia; AD, Alzheimer’s disease; 
Verbal memory recall composite score comprised of scores from the address learning, 
delayed address recall, and retrograde memory measures of the ACE-R and the STPR and 
LTPR measures of the RAVLT; Verbal memory recognition composite score comprised of 
ACE-R address recognition and RAVLT list recognition; Non-verbal memory recall 
composite score comprised of the ROCF three-minute delayed recall; Non-verbal memory 
recognition composite score comprised of the Doors Test A raw scores 
 
